Chronic Hepatitis C Virus infection
Medically Reviewed by Dr. M. Salar Raza | Official SCFHS 2026 Blueprint
Clinical Pathway
Chronic Hepatitis C Virus (HCV) infection is a persistent inflammatory condition of the liver caused by the hepatitis C virus, defined by the presence of detectable HCV RNA for at least six months. This long-term infection can progressively lead to significant liver damage, including fibrosis, cirrhosis, and hepatocellular carcinoma. Current treatment primarily involves direct-acting antiviral (DAA) medications, which are highly effective oral regimens targeting specific viral proteins to inhibit HCV replication. These therapies typically achieve a sustained virologic response (SVR) in over 95% of patients, effectively curing the infection. Treatment duration usually ranges from 8 to 12 weeks, depending on the specific regimen and patient factors. Chronic HCV infection is often asymptomatic for many years, leading to a silent progression of liver disease. When symptoms do appear, they are often non-specific, such as fatigue, malaise, nausea, and right upper quadrant discomfort. As the disease advances to cirrhosis, signs of liver decompensation may emerge, including jaundice, ascites, peripheral edema, spider angiomata, and hepatic encephalopathy.
Clinical Reasoning
The hepatitis C virus is an RNA virus that primarily infects hepatocytes. Upon entry, the virus replicates within the host cells, triggering both innate and adaptive immune responses. In chronic infection, the immune system fails to clear the virus, leading to ongoing hepatocyte damage, inflammation, oxidative stress, and the accumulation of extracellular matrix proteins, which drives progressive hepatic fibrosis. With the advent of modern DAA therapies, the prognosis for chronic HCV infection is excellent, with the vast majority of patients achieving a cure and preventing further liver damage. For those with established cirrhosis, successful treatment can halt disease progression, improve liver function, and significantly reduce the risk of hepatocellular carcinoma, although continued surveillance for cancer may still be necessary. Intravenous drug use (sharing needles, syringes, or drug paraphernalia),Transfusion of blood or blood products before 1992 (when universal screening began),Unsterile tattooing or body piercing practices,Sharing personal care items (e.g., razors, toothbrushes) contaminated with blood,Occupational exposure to blood (e.g., healthcare workers needlestick injuries),Being born to an HCV-infected mother
Sample MCQ
A patient with decompensated cirrhosis secondary to chronic Hepatitis C virus infection presents with persistent, recurrent ascites requiring frequent large-volume paracentesis for symptom management. What is the appropriate dietary advice?
- ADietary protein restriction to less than 0.8 g/kg per day
- BDietary fat restriction to less than 20% of total daily calories
- CUniversal fluid restriction to less than 1 liter per day
- DDietary sodium restriction to less than 2 grams (88 mmol) per day
Correct Answer: D
### TLDR For patients with decompensated cirrhosis and recurrent ascites, dietary sodium restriction is the cornerstone of management. This approach directly combats fluid retention, which is driven by sodium accumulation, and significantly enhances the efficacy of diuretic therapy. ### Comparison Table | Option | Mechanism | Clinical Nuance | Key Distinction | | :----- | :-------- | :-------------- | :---------------- | | Dietary protein restriction to less than 0.8 g/kg per day | Reduces ammonia production; historically for encephalopathy. | Not recommended for chronic HE; worsens malnutrition in cirrhosis. | Malnutrition risk high; not for ascites treatment. | | Dietary fat restriction to less than 20% of total daily calories | Limits fat intake; may address steatorrhea or hyperlipidemia. | Not primary for ascites management; malnutrition concern in cirrhosis. | Unrelated to ascites pathophysiology. | | Universal fluid restriction to less than 1 liter per day | Decreases total body water; reduces dilutional hyponatremia. | Only for severe hyponatremia (Na<120-125); not routine for ascites. | Sodium is the primary driver of ascites, not free water. | | **Dietary sodium restriction to less than 2 grams (88 mmol) per day** | **Reduces total body sodium, decreasing water retention and ascites.** | **Cornerstone of ascites management; enhances diuretic efficacy.** | **Directly targets fluid retention in cirrhosis.** | ### Detailed Breakdown The correct answer is **Dietary sodium restriction to less than 2 grams (88 mmol) per day**. This is the most crucial dietary intervention for managing ascites in patients with decompensated cirrhosis. In cirrhosis, portal hypertension and splanchnic vasodilation lead to effective arterial hypovolemia, activating the renin-angiotensin-aldosterone system and sympathetic nervous system. This results in renal retention of sodium and water, leading to ascites formation. Limiting dietary sodium directly reduces the total body sodium load, thereby decreasing water retention and the accumulation of ascetic fluid. This strategy significantly improves the effectiveness of diuretic therapy, allowing for better ascites control and reducing the need for frequent large-volume paracentesis. Let's consider why the other options are less appropriate: * **Dietary protein restriction to less than 0.8 g/kg per day:** While protein restriction was historically used for hepatic encephalopathy (HE), current guidelines generally advise against it. Patients with cirrhosis are often malnourished, and protein restriction can exacerbate this, worsening muscle wasting and overall prognosis. Most patients with HE can tolerate a normal or even high-protein diet (1.2-1.5 g/kg/day), with treatment focusing on lactulose and rifaximin. It is not a primary treatment for ascites. * **Dietary fat restriction to less than 20% of total daily calories:** Restricting dietary fat is not a primary intervention for ascites. While some patients with advanced liver disease may experience fat malabsorption due to cholestasis, a blanket fat restriction isn't indicated for ascites management and could contribute to malnutrition. * **Universal fluid restriction to less than 1 liter per day:** Fluid restriction is generally *not* recommended for the routine management of ascites. It is primarily reserved for patients with severe dilutional hyponatremia (typically serum sodium <120-125 mmol/L) to prevent further drops in serum sodium concentration. In the absence of severe hyponatremia, fluid restriction offers little benefit in ascites control and can be challenging for patients, impairing quality of life without significant clinical advantage over sodium restriction and diuretics. Sodium, not free water, is the main driver of ascites.
Related Clinical Topics
AIDS
AIDS (Acquired Immunodeficiency Syndrome) is the final, most severe stage of HIV infection, characterized by a profoundly compromised immune system that makes individuals highly susceptible to opportunistic infections and certain cancers. It is diagnosed when the CD4+ T-cell count drops below 200 cells/mm³ or when specific AIDS-defining opportunistic illnesses develop. The cornerstone of AIDS treatment is highly active antiretroviral therapy (HAART), a combination of drugs that suppress HIV replication, preserve immune function, and prevent further progression. HAART significantly reduces viral load, increases CD4+ T-cell counts, and improves overall health. Treatment also includes prophylactic antibiotics to prevent opportunistic infections and specific therapies for any active infections or cancers. Symptoms of AIDS are primarily due to the opportunistic infections and cancers that take advantage of the severely weakened immune system. Common manifestations include persistent fever, chronic diarrhea, significant unintentional weight loss, night sweats, fatigue, swollen lymph nodes, and recurrent severe infections like Pneumocystis pneumonia, Kaposi's sarcoma, and toxoplasmosis. Neurological complications such as AIDS dementia complex can also occur.
Bradycardia
Bradycardia is a medical condition characterized by a slower than normal heart rate, typically defined as fewer than 60 beats per minute (bpm) in adults. While sometimes physiological and benign, it can also indicate underlying cardiovascular or systemic issues that impair the heart's ability to effectively pump blood. Treatment for bradycardia depends on its underlying cause, severity, and the presence of symptoms. Asymptomatic bradycardia, especially in athletes, often requires no intervention. Symptomatic bradycardia may necessitate discontinuing or adjusting causative medications, treating underlying conditions, or in severe cases, implanting a permanent pacemaker to regulate heart rhythm. Acute, unstable bradycardia may require intravenous atropine or temporary pacing. Clinical manifestations range from asymptomatic presentation to severe symptoms depending on the degree of bradycardia and the patient's cardiovascular reserve. Common symptoms include fatigue, dizziness, lightheadedness, syncope (fainting), shortness of breath, and chest pain. In critical cases, it can lead to confusion, hypotension, and signs of organ hypoperfusion.
Chronic hypertension
Chronic hypertension is a persistent and sustained elevation of blood pressure, typically defined as a systolic blood pressure greater than or equal to 130 mmHg or a diastolic blood pressure greater than or equal to 80 mmHg on multiple occasions. It is a major modifiable risk factor for various cardiovascular diseases, stroke, and kidney disease. Treatment for chronic hypertension involves a multi-faceted approach, starting with lifestyle modifications such as dietary changes (e.g., DASH diet), regular physical activity, weight loss, and reduced sodium and alcohol intake. Pharmacological therapy is often necessary and may include various classes of antihypertensive medications like diuretics, ACE inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and calcium channel blockers, frequently used in combination to achieve target blood pressure. Chronic hypertension is often referred to as 'the silent killer' because it is frequently asymptomatic for many years, even at high levels. When symptoms do occur, they are typically non-specific and may include headaches, dizziness, nosebleeds, or shortness of breath, usually manifesting in severe or long-standing cases or during a hypertensive crisis. Most diagnoses are made during routine medical screenings.
SMLE Preparation Resources
Master the 2026 SMLE
Explore more clinical protocols in the SMLEREVISE Clinical Knowledge Library.
Try the QBank & Scaled Mocks